Use of a combination of docetaxel (Tautax and Taxotere) and etoposide plus prednisolone versus docetaxel monotherapy in the treatment of patients with hormone-resistant prostate cancer

A A Gritskevich , V L Medvedev , I G Rusakov , S V Bystrov , A A Gritskevich , V L Medvedev , I G Rusakov , S V Bystrov

Russian Journal of Oncology ›› 2011, Vol. 16 ›› Issue (2) : 28 -32.

PDF
Russian Journal of Oncology ›› 2011, Vol. 16 ›› Issue (2) : 28 -32. DOI: 10.17816/onco39840
Articles
other

Use of a combination of docetaxel (Tautax and Taxotere) and etoposide plus prednisolone versus docetaxel monotherapy in the treatment of patients with hormone-resistant prostate cancer

Author information +
History +
PDF

Abstract

The efficacy and safety of a combination of docetaxel and etoposide plus prednisolone versus docetaxel monotherapy were studied in patients with hormone-resistant prostate cancer.The patients were divided into 2 groups: 1) 24 patients received docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day; 2) 21 patients used docetaxel 75 mg/m2 once every 3 weeks + prednisolone 10 mg/day + intravenous etoposide 100 mg/m2 on days 1 to 5. The patients' age ranged from 45 to 81 years (mean age 64.9 years). The study has shown that docetaxel monotherapy has benefits in terms of treatment response duration, overall survival, and satisfactory therapy tolerability.

Keywords

hormone-resistant prostate cancer / chemotherapy / docetaxel / etoposide

Cite this article

Download citation ▾
A A Gritskevich, V L Medvedev, I G Rusakov, S V Bystrov, A A Gritskevich, V L Medvedev, I G Rusakov, S V Bystrov. Use of a combination of docetaxel (Tautax and Taxotere) and etoposide plus prednisolone versus docetaxel monotherapy in the treatment of patients with hormone-resistant prostate cancer. Russian Journal of Oncology, 2011, 16(2): 28-32 DOI:10.17816/onco39840

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Русаков И. Г., Алексеев Б. Я. // Соврем. онкол. - 2004. - Т. 6, № 3. - С. 116-121.

[2]

Чиссов В. И. Онкологическая заболеваемость и смертность. - М., 2008.

[3]

Abrahamson Per-Anders. // Eur. Urol. - 2003. - Suppl. 2. - P. 1-2.

[4]

Benson R., Hartley-Asp B. // Cancer Invest. - 1990. - Vol. 8. - P. 375-380.

[5]

Dahllof B., Billstrom A., Cabral F., Hartley-Asp. B. // Cancer Res. - 1993. - Vol. 53. - P. 4573-4581.

[6]

Earhart R. H. // Semin. Oncol. - 1999. - Vol. 26. - P. 8-13.

[7]

Eisenberger M. A., Simon R., O'Dwyer P. J. et al. // J. Clin. Oncol. - 1985. - Vol. 3. - P. 827-841.

[8]

Garnick M. B. // Ann. Intern. Med. - 1993. - Vol. 118. - P. 804-818.

[9]

Heidenreich A., Schrader A. J. // EAU Update Ser. 1. - 2003. - P. 40-50.

[10]

Iversen P. // Eur. Urol. - 2000. - Suppl. 2. - P. 3-8.

[11]

Petrylak D. P., Tangen C. M., Hussain M. H. et al. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1515-1520.

[12]

Tannock I. F., de Wit R., Berry W. J. et al. // N. Engl. Med. - 2004. - Vol. 351. - P. 1502-1512.

[13]

Yagoda A., Petrylak D. // Cancer. - 1993. - Vol. 71. - P. 1098-1109.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

142

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/